Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV001 in Healing of Incisional Wounds
NCT03639883Phase 1Completed
- Sponsor
- AiViva BioPharma
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AIV001 in scar (4 arms), sponsored by AiViva BioPharma. Primary endpoint: Adverse events. Started Nov 2018; status: completed.
02
Drugs
AIV001
03
Conditions
scar
Beyond the preview
Go deeper on NCT03639883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639883.